Automate Your Wheel Strategy on HOLX
With Tiblio's Option Bot, you can configure your own wheel strategy including HOLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HOLX
- Rev/Share 18.2848
- Book/Share 22.5099
- PB 3.3279
- Debt/Equity 0.4968
- CurrentRatio 3.7537
- ROIC 0.0738
- MktCap 16697830629.0
- FreeCF/Share 4.3621
- PFCF 17.07
- PE 29.6902
- Debt/Assets 0.2782
- DivYield 0
- ROE 0.1174
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HOLX | BNP Paribas Exane | Outperform | Neutral | -- | $79 | Nov. 21, 2025 |
| Upgrade | HOLX | Evercore ISI | In-line | Outperform | -- | $78 | Oct. 7, 2025 |
| Upgrade | HOLX | Argus | Hold | Buy | -- | $80 | Aug. 18, 2025 |
| Upgrade | HOLX | RBC Capital Mkts | Sector Perform | Outperform | -- | $87 | Aug. 6, 2025 |
| Upgrade | HOLX | Citigroup | Neutral | Buy | -- | $80 | July 9, 2025 |
| Reiterated | HOLX | Needham | -- | Hold | -- | -- | May 27, 2025 |
| Downgrade | HOLX | Argus | Buy | Hold | -- | -- | March 3, 2025 |
| Downgrade | HOLX | Leerink Partners | Outperform | Market Perform | $80 | $75 | Feb. 6, 2025 |
| Downgrade | HOLX | Needham | Buy | Hold | -- | -- | Feb. 3, 2025 |
| Initiation | HOLX | Wolfe Research | -- | Peer Perform | -- | -- | Dec. 13, 2024 |
News
HOLX Stock Down 24.7% in 6 Months: Time to Cut Losses or Buy the Dip?
HOLX
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive
As Hologic works through the changing macroeconomic and geopolitical landscape, its long-term potential makes it a solid hold.
Read More
Why Is Hologic (HOLX) Down 4.5% Since Last Earnings Report?
HOLX
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?
Read More
Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software
HOLX
Published: February 20, 2025 by: Business Wire
Sentiment: Neutral
Published: February 20, 2025 by: Business Wire
Sentiment: Neutral
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #cemark--Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software.
Read More
Two S&P 500 hidden gems to buy right now
HOLX,
SNPS
Published: February 18, 2025 by: Finbold
Sentiment: Positive
Published: February 18, 2025 by: Finbold
Sentiment: Positive
Although the benchmark S&P 500's biggest names tend to dominate investor attention, the index also features lesser-known stocks with significant growth potential.
Read More
HOLX's New Offerings Likely to Revive Stock Amid Macro Woes
HOLX
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic's Surgical business has been recording strong broad-based performance by expanding access to technologies into new global markets.
Read More
Here's Why You Should Retain HOLX Stock in Your Portfolio Now
HOLX
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic's strength in the molecular diagnostics wing instills optimism among investors. Yet, a dull macroeconomic environment raises concerns.
Read More
About Hologic, Inc. (HOLX)
- IPO Date 1990-03-01
- Website https://www.hologic.com
- Industry Medical - Instruments & Supplies
- CEO Stephen MacMillan
- Employees 7063
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.